News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS)

Al's Comment:

 This is a very important trial - hopefully it will allow GBM patients who happen to have the "bad" markers to do as well (or better) than the current standard of care does with GBM patients who have the "good" markers!


Posted on: 05/08/2017

 

DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS)

 

www.prnewswire.com/news-releases/delmar-presents-new-mechanism-of-action-data-for-its-lead-agent-val-083-in-temozolomide-resistant-glioblastoma-multiforme-gbm-at-the-world-federation-of-neuro-oncology-societies-wfnos-300452896.html

 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740